Skip to content

Medical emergency? What to do

Lipitor fails to beat Zocor in heart study

3-RXPublished November 15, 20052 min read

Key points

  • High doses of Pfizer Inc.'s cholesterol-lowering drug Lipitor failed in a high-stakes trial to help heart attack patients significantly more than moderate doses of Merck & Co.'s rival Zocor, researchers said on Tuesday.
  • The 80-milligram Lipitor group, however, did show a highly statistically significant reduction in nonfatal heart attacks and strokes compared to patients taking 20 mg to 40 mg of Zocor, the report added.
  • There was no significant difference in death by causes not related to heart or vascular problems between the two groups, the Pfizer-funded study concluded.
  • Lipitor is the world's biggest-selling prescription medicine with sales approaching of $12 billion annually.

High doses of Pfizer Inc.'s cholesterol-lowering drug Lipitor failed in a high-stakes trial to help heart attack patients significantly more than moderate doses of Merck & Co.'s rival Zocor, researchers said on Tuesday.

The aim of the study presented at the American Heart Association scientific meeting was to determine whether intensive lowering of "bad" LDL cholesterol with atorvastatin (Lipitor) would reduce the risk of death and other adverse events in heart attack patients more than the moderate, most widely used dose of Zocor, known by the chemical name simvastatin.

Instances of death, acute heart attack or cardiac arrest requiring resuscitation occurred in 10.4 percent of the Zocor group and 9.3 percent of the high-dose group, differences not considered statistically significant, researchers said.

The 80-milligram Lipitor group, however, did show a highly statistically significant reduction in nonfatal heart attacks and strokes compared to patients taking 20 mg to 40 mg of Zocor, the report added.

Non-fatal heart attacks were reduced by 17 percent in the Lipitor group.

There was no significant difference in death by causes not related to heart or vascular problems between the two groups, the Pfizer-funded study concluded.

"This finding may help calm concerns that high-dose statins contribute to excess non-cardiac deaths, such as from cancer, but benefits apparent in this trial were more modest than we had expected," said Dr. Terje Pedersen, the study's lead author.

Lipitor is the world's biggest-selling prescription medicine with sales approaching of $12 billion annually.

A decisive victory for Lipitor might have been a persuasive argument for keeping doctors and insurance companies from attempting to switch patients from Lipitor to cheaper generic versions of Zocor after Merck's blockbuster cholesterol drug goes off patent next year.

Pfizer shares were down 40 cents, or 1.8 percent, to $21.85 on the New York Stock Exchange.

Pedersen did say that if researchers had continued the study for another three months, Lipitor might have achieved the main goal of the trial. He added that the primary goal was more heavily weighted toward death rates than was the secondary goal.

The large trial was conducted on more than 8,800 heart attack patients from 1999 to 2005 in Northern Europe by researchers at Norway's Ulleval University Hospital in Oslo.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.